Lack of correlation between impaired interferon production and natural killer activity of lymphocytes in multiple sclerosis

The ability of lymphocytes from patients with multiple sclerosis (MS) to produce Interferon (IFN-alpha) in response to Newcastle Disease Virus (NDV) was studied in vitro. The correlation between individual IFN-alpha titers and natural killer (NK) cell activity and the presence of HLA system antigens...

Full description

Saved in:
Bibliographic Details
Published in:Archives of virology 1982-01, Vol.71 (3), p.259-265
Main Authors: Stöger, I, Tálas, M, Benczúr, M, Gyódi, E, Petrányi, G G, Pálffy, G, Kotsy, B
Format: Article
Language:English
Subjects:
Adolescent
Adult
Cytotoxicity, Immunologic
Female
HLA Antigens - immunology
Humans
Interferons - deficiency
Killer Cells, Natural - immunology
Lymphocytes - immunology
Lymphocytes - metabolism
Male
Middle Aged
Multiple Sclerosis - immunology
Newcastle disease virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The ability of lymphocytes from patients with multiple sclerosis (MS) to produce Interferon (IFN-alpha) in response to Newcastle Disease Virus (NDV) was studied in vitro. The correlation between individual IFN-alpha titers and natural killer (NK) cell activity and the presence of HLA system antigens associated with MS (B-7 and DRW-2) was also investigated. Lymphocytes from MS patients showed a significantly impaired capacity to synthesize IFN-alpha in vitro when compared to lymphocytes from healthy donors (mean titers: 85.9 I.U. and 268.2 I.U., respectively). Marked differences in IFN-alpha titers were observed in the group of MS patients. The production of IFN-alpha by the patients' lymphocytes did not correlate with either the activity of NK cells or with their stimulation by exogenous IFN-alpha. There was also no correlation between IFN-alpha production by lymphocytes from MS patients and the presence or absence of B-7 and DRW-2 antigens.
ISSN:0304-8608
1432-8798
DOI:10.1007/BF01314877